Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American Heart Association In Brief: Perclose

This article was originally published in The Gray Sheet

Executive Summary

Perclose: Four hundred-patient study presented at AHA finds that the firm's Techstar percutaneous vascular surgical closure device is associated with a "statistically significant reduction of major and minor complications" versus manual compression, Perclose says. A study of 400 diagnostic catheterization patients found that major complications occurred in 0.5% of Techstar patients and 2.5% of manual compression patients. Minor complication rates were 3.9% and 10.1% for Techstar and non-Techstar patients, respectively. The study also found a reduced time to ambulation (1 hour vs. 20.3 hours) in the Techstar group. A second, 200-patient study evaluating use of Techstar in angioplasty and stent procedures also finds faster ambulation time (4.1 hours vs. 14.7 hours) in the Techstar group...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel